Avalo Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Avalo Therapeutics CEO'su Garry Neil, Feb2022 tarihinde atandı, in görev süresi 2.75 yıldır. in toplam yıllık tazminatı $ 1.08M olup, şirket hissesi ve opsiyonları dahil olmak üzere 44.2% maaş ve 55.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.001% ine doğrudan sahiptir ve bu hisseler € 563.95 değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 2.7 yıldır.

Anahtar bilgiler

Garry Neil

İcra Kurulu Başkanı

US$1.1m

Toplam tazminat

CEO maaş yüzdesi	44.2%
CEO görev süresi	2.8yrs
CEO sahipliği	0.0006%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	2.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Garry Neil'un ücretlendirmesi Avalo Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$8m
Jun 30 2024	n/a	n/a	-US$19m
Mar 31 2024	n/a	n/a	-US$49m
Dec 31 2023	US$1m	US$475k	-US$32m
Sep 30 2023	n/a	n/a	-US$33m
Jun 30 2023	n/a	n/a	-US$25m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$1m	US$469k	-US$42m
Sep 30 2022	n/a	n/a	-US$51m
Jun 30 2022	n/a	n/a	-US$72m
Mar 31 2022	n/a	n/a	-US$76m
Dec 31 2021	US$1m	US$423k	-US$84m
Sep 30 2021	n/a	n/a	-US$81m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$73m
Dec 31 2020	US$3m	US$373k	-US$64m

Tazminat ve Piyasa: Garry 'nin toplam tazminatı ($USD 1.08M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 476.59K ).

Tazminat ve Kazançlar: Garry 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Garry Neil (70 yo)

2.8yrs

Görev süresi

US$1,075,362

Tazminat

Dr. Garry A. Neil, M.D., serves as the Member of Scientific Advisory Board of Rapafusyn Research And Development, Inc. Dr. Garry serves as Independent Director of Celldex Therapeutics, Inc. since June 16,...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Garry Neil	Chairman of the Board	2.8yrs	US$1.08m	0.00057% € 564.0
Christopher Sullivan	CFO & Head of Investor relations	2.8yrs	US$607.65k	0.000060% € 59.4
Solomon Snyder	Founder and Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Barbara Slusher	Founder and Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Paul Varki	Chief Legal Officer	less than a year	Veri yok	Veri yok
Lisa Hegg	Senior Vice President of Program Management	2.8yrs	Veri yok	Veri yok
Colleen Matkowski	Senior Vice President of Global Regulatory Affairs & Quality Assurance	2.8yrs	Veri yok	Veri yok
Dino Miano	Senior Vice President of CMC & Technical Operations	2.8yrs	Veri yok	Veri yok
Mittie Doyle	Chief Medical Officer	less than a year	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: C6K0 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Garry Neil	Chairman of the Board	2.4yrs	US$1.08m	0.00057% € 564.0
Solomon Snyder	Founder and Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Barbara Slusher	Founder and Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Sol Barer	Special Advisor & Strategic Advisory Board	3.4yrs	US$133.94k	Veri yok
Gilla Kaplan	Independent Director	4.1yrs	US$60.12k	0% € 0
Ronald Borchardt	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Lenox	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Anne Young	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Dennis Liotta	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Aaron Kantoff	Independent Director	less than a year	Veri yok	Veri yok
Samantha Truex	Independent Director	less than a year	Veri yok	Veri yok
Mitchell Chan	Independent Director	2.9yrs	US$60.12k	0% € 0

2.7yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: C6K0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.7 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Avalo Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Avalo Therapeutics, Inc. Appoints Mittie Doyle as Chief Medical Officer

Avalo Therapeutics, Inc., Annual General Meeting, Aug 13, 2024

Avalo Therapeutics, Inc. Appoints Paul Varki as Chief Legal Officer

Avalo Therapeutics, Inc. Announces Board Appointments

Avalo Therapeutics, Inc., Annual General Meeting, Dec 05, 2023

Insider recently bought €52k worth of stock

Recent updates

Avalo Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Lotus Trial of Avtx-009 for the Treatment of Hidradenitis Suppurativa

Avalo Therapeutics, Inc. Appoints Mittie Doyle as Chief Medical Officer

Avalo Therapeutics Announces Active IND for AVTX-009, an Anti-IL-1ß mAb, to Treat Hidradenitis Suppurativa

Avalo Therapeutics, Inc., Annual General Meeting, Aug 13, 2024

Avalo Therapeutics, Inc. Appoints Paul Varki as Chief Legal Officer

Avalo Therapeutics Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Stockholders' Equity Requirement

Avalo Therapeutics, Inc. Announces Board Appointments

Hearings Panel Grants Avalo Therapeutics an Exception from Compliance with the MVLS Rule and the Bid Price Rule and Extension of Continued Listing Until December 29, 2023

Avalo Therapeutics, Inc., Annual General Meeting, Dec 05, 2023

Nasdaq Determines to Delist Securities of Avalo Therapeutics

AUG Therapeutics, LLC entered into a purchase agreement to acquire rights, title and interest in, assets relating to AVTX-800 Series from Avalo Therapeutics, Inc. (NasdaqCM:AVTX).

Avalo Therapeutics, Inc. Receives Notice from Nasdaq Regarding Bid Price Rule

New major risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$1.38 loss in 2Q 2022)

New minor risk - Insider selling

New major risk - Revenue and earnings growth

Avalo Announces Topline Data from Phase 2 Peak Trial for Avtx-002 (Quisovalimab) in Patients with Non-Eosinophilic Asthma

Insider recently bought €52k worth of stock

Insider recently bought €83k worth of stock

Insider recently bought €63k worth of stock

First quarter 2023 earnings released: US$0.85 loss per share (vs US$2.35 loss in 1Q 2022)

Insider recently bought €49k worth of stock

Insider recently bought €131k worth of stock

Full year 2022 earnings released

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering.

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering.

Avalo Therapeutics, Inc. Completes Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

High number of new and inexperienced directors

Forecast to breakeven in 2024

Third quarter 2022 earnings released: EPS: US$0.34 (vs US$2.04 loss in 3Q 2021)

High number of new and inexperienced directors

Avalo Therapeutics, Inc. Advances B and T Lymphocyte Attenuator Agonist Fusion Protein (AVTX-008) to IND-Enabling Stage

Avalo Therapeutics Announces Board Changes

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

Avalo Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.32 loss in 1Q 2021)

Avalo Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Avalo Therapeutics, Inc. Announces Executive and Board Changes

Avalo Therapeutics, Inc. Announces Chief Executive Officer Changes

Avalo Therapeutics, Inc. Announces Resignation of H. Jeffrey Wilkins as Chief Medical Officer

Avalo Therapeutics, Inc. Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2020)

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $27.5 million.

Avalo Therapeutics, Inc.(NasdaqCM:AVTX) dropped from NASDAQ Composite Index

Second quarter 2021 earnings released: US$0.88 loss per share (vs US$0.19 loss in 2Q 2020)

High number of new directors

Cerecor Inc. announced that it expects to receive $35 million in funding from Horizon Technology Finance Management, LLC

First quarter 2021 earnings released: US$0.32 loss per share (vs US$0.36 loss in 1Q 2020)

Forecast to breakeven in 2024

U.S. Food and Drug Administration Grants Fast Track Designation to CERC-002 of Cerecor Inc. for Treatment of Hospitalized Patients with COVID-19

Cerecor Inc. Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease

Full year 2020 earnings released: US$0.88 loss per share (vs US$0.28 loss in FY 2019)

Revenue beats expectations

Cerecor Inc. Announces Final Efficacy Data Including 60-Day Mortality from Their Recently Completed Us-Based, Multi-Center (10 Sites)

Cerecor Inc. Appoints Schond L. Greenway as Chief Financial Officer

New 90-day high: €3.56

New 90-day high: €3.16

Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II

New 90-day high: €2.72

Cerecor Inc. Announces Successful Proof of Concept Data for CERC-002, a Unique LIGHT-Neutralizing Antibody, in Patients Hospitalized with COVID-19 ARDS

New 90-day high: €2.26

Cerecor Inc. Announces First Patient Dosed in A Phase 1B Clinical Trial of Cerc-007 for the Treatment of Relapsed or Refractory Multiple Myeloma

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for Treatment of Relapsed or Refractory Multiple Myeloma

Cerecor Inc. Enters into an Amendment to Its Existing License and Supply Agreement with Watson Laboratories, Inc

Cerecor Inc. Appoints Gilla Kaplan, to Its Board of Directors

Cerecor Inc. Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease

CEO Tazminat Analizi